In almost all disease processes in biological systems, changes in protein phosphorylation have an inherent cause-and-effect in onset, progression and decline. KScan®’s ability to reveal the phosphoproteomic signatures of network circuitry gives powerful insights in many therapeutic areas.
Peripheral Blood (PBMC)
Kinomica’s services in Oncology drug development deliver identification of targets, mode of action studies, off-target effects, drug resistance mechanisms and improved patient stratification for Clinical Trials.
Talk to our Experts
To find out more about the technology behind Kinomica’s advanced bioinformatics and phosphoproteomics analytical methods, talk to our experts.
If you have any questions or need any further information, then please contact the Kinomica team – we are more than happy to help.
“Our groundbreaking technology driven by deep expertise and powerful insights provides a direct snapshot of protein and cell-signalling activity, with data that demonstrates we can predict drug response far more accurately than current gene mutation markers”
Anthony Sullivan, Business Development Director